title: Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center.
abstract: BACKGROUND
  Respiratory signs and symptoms are commonly encountered by physicians who care for cancer patients. Supplemental oxygen (SOx) has long been used for treatment of hypoxic respiratory insufficiency, but data reveal mixed efficacy results. The use and outcome patterns of technologically advanced oxygen delivery devices, such as humidified high-flow nasal oxygen (HHFNOx), are incompletely understood.
  
  
  METHODS
  Institutional database search of the number of patient cases in which the current HHFNOx device was used, and abstraction of 183 patient medical records for usage characteristics.
  
  
  RESULTS
  Patients have been treated with HHFNOx at Memorial Sloan Kettering Cancer Center (MSKCC) since 2008. Of the 183 patients randomly selected for our study, 72% received HHFNOx in the intensive care unit (ICU) because of hypoxia. Patients usually improved (41%) or remained stable (44%) while on the device, whereas 15% declined. At study completion, 45% of patients were living, and 55% had died. The median time on HHFNOx was 3 days (range: 1-27). A do not resuscitate (DNR) order was present in 101 (55%) patients, either before (12%) or after (43%) device utilization. The majority (78%) of these 101 patients died at MSKCC.
  
  
  CONCLUSIONS
  Dyspnea is a common and important symptom in cancer patients for which SOx traditionally has had no clear basis except in select cases of hypoxia and patient preference. Our institutional experience with HHFNOx contributes to the understanding of the applications and challenges surrounding the use of new medical devices in the cancer population. Physiologic and quality-of-life benefits of HHFNOx compared with traditional oxygen delivery methods should be studied prospectively.
authors: Memorial Sloan-Kettering Cancer Center , New York, NY 10065, USA.
authors: Andrew S
authors: AS
authors: Epstein
authors: Sidonie K
authors: SK
authors: Hartridge-Lambert
authors: Judson S
authors: JS
authors: Ramaker
authors: Louis P
authors: LP
authors: Voigt
authors: Carol S
authors: CS
authors: Portlock
references: Br J Anaesth. 2009 Dec;103(6):886-90
references: 19846404
references: Ann Intern Med. 2008 Jan 15;148(2):141-6
references: 18195338
references: Respir Care. 2010 Apr;55(4):408-13
references: 20406507
references: Respir Care. 2008 Dec;53(12):1739-43
references: 19025711
references: Chest. 2010 Mar;137(3):674-91
references: 20202949
references: Palliat Med. 2003 Dec;17(8):659-63
references: 14694916
references: J Palliat Med. 2008 May;11(4):601-9
references: 18454613
references: J Pain Symptom Manage. 2009 Mar;37(3):429-32
references: 19268813
references: Support Care Cancer. 2009 Apr;17(4):367-77
references: 18719948
references: Palliat Med. 2005 Mar;19(2):168-70
references: 15810762
references: Respir Med. 2004 Jan;98(1):66-77
references: 14959816
references: J Clin Oncol. 2008 May 10;26(14):2396-404
references: 18467732
references: Br J Cancer. 2008 Jan 29;98(2):294-9
references: 18182991
references: Support Care Cancer. 2010 Jun;18(6):765-70
references: 20306274
references: Palliat Med. 2009 Jun;23(4):309-16
references: 19304806
references: J Palliat Care. 2004 Winter;20(4):303-7
references: 15690833
references: Cancer Nurs. 2007 Mar-Apr;30(2):E1-8
references: 17413770
references: Lancet. 2010 Sep 4;376(9743):784-93
references: 20816546
references: Eur J Cancer. 2008 May;44(8):1116-23
references: 18424030
references: J Crit Care. 2010 Sep;25(3):463-8
references: 19781896
references: J Pain Symptom Manage. 2006 Dec;32(6):541-50
references: 17157756